Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endovascular Aortic Repair for Aortic Dissection

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2012 by Xijing Hospital
Sponsor:
Collaborator:
Changhai Hospital
Information provided by (Responsible Party):
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01505309
First received: December 22, 2011
Last updated: January 5, 2012
Last verified: January 2012

December 22, 2011
January 5, 2012
January 2008
December 2014   (final data collection date for primary outcome measure)
Cumulative major adverse cardiac events (MACE) [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Cumulative MACE (including death, rupture, paraplegia, aneurysm formation et al)
Same as current
Complete list of historical versions of study NCT01505309 on ClinicalTrials.gov Archive Site
  • Endoleak [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Endoleak of all types from the stent graft
  • Stent-graft migration/kinking [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Stent-graft migration, stenosis, kinking and other conditions requiring re-intervention
Same as current
Not Provided
Not Provided
 
Endovascular Aortic Repair for Aortic Dissection
Endovascular Aortic Repair for Aortic Dissection------XiJing Registry

The purpose of this study is to investigate the short to mid term efficacy and safety of Thoracic Endovascular Aortic Repair (TEVAR) in patients who had aortic lesions, such as descending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Aneurysms and dissection involving the descending aorta and aortic arch have historically been treated with open surgical techniques, requiring cardiopulmonary bypass and deep hypothermic circulatory arrest (DHCA). Despite increasing experience and refinement of these procedures, there remains a substantial rate of morality and morbidity. The goal of Thoracic Endovascular Aortic Repair (TEVAR) is to re-construct the descending aorta and aortic arch to cover the primary entry tear of the dissection and to remodel the aorta. TEVAR technique were performed with various devices available. The purpose of this study is to investigate the short to mid term efficacy and safety of Thoracic Endovascular Aortic Repair (TEVAR) in patients who had aortic lesions, such as descending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type B dissection,dissection with primary tear located in the aortic arch, et al.

Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (> 5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study designs to enroll 50 patients to be monitored for 24 months.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Aorta Dissection
  • Aorta Aneurysm
Device: Stent Graft (Medtronic, Microport, Ankura)
Medtronic Stent Graft(Medtronic Medtronic, Inc., US) Microport Stent Graft(Microport Co.,LTD.,Shanghai, China) Ankura Stent Graft(Lifetech Scientific Co.,LTD.,Shenzhen, China)
Other Names:
  • Medtronic Stent Graft
  • Microport Stent Graft
  • Ankura Stent Graft
Experimental: Stent Graft
TEVAR procedure using devices include Medtronic Stent Graft(Medtronic Medtronic, Inc., US) Microport Stent Graft(Microport Co.,LTD.,Shanghai, China) Ankura Stent Graft(Lifetech Scientific Co.,LTD.,Shenzhen, China).
Intervention: Device: Stent Graft (Medtronic, Microport, Ankura)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
December 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Descending aortic/arch aneurysm
  • Descending aortic/arch pseudo-aneurysm
  • Stanford Type B dissection
  • Unclassified dissection with primary tear located in the aortic arch
  • Able to tolerate endotracheal intubation and general anesthesia
  • Subject's anatomy must meet the anatomical criteria to receive that implanted device
  • The subject or legal guardian understands the nature of the study and agrees to its provisions on a written informed consent form
  • Availability for the appropriate follow-up visits during the follow-up period
  • Capability to follow all study requirements

Exclusion Criteria:

  • ASA classification = V
  • Severe renal insufficiency defined as SVS risk renal status = 3
  • Severe respiratory insufficiency defined as SVS risk pulmonary status = 3
  • Presence of connective tissue disease
  • Active infection or active vasculitides
  • Pregnant woman or positive pregnancy test
  • Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment
  • Subject has had a cerebral vascular accident (CVA) within 2 months.
  • History of drug abuse
  • Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
  • Subject has a known allergy or intolerance to the device components.
  • Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.
  • Subject has a co-morbidity causing expected survival to be less than 1 year.
  • Enrollment in another clinical study
  • Unwillingness to cooperate with study procedures or follow-up visits
Both
12 Years to 90 Years
No
Contact: Jian Yang, MD,PhD 86-13892828016 yangjian1212@hotmail.com
China
 
NCT01505309
XJ-20111126 -3
Yes
Xijing Hospital
Xijing Hospital
Changhai Hospital
Principal Investigator: Jian Yang, M.D., Ph.D Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Xijing Hospital
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP